‹

01 The mission: For Partners

Great partners attract
great science.

02 The Advisors

Strengthen your team

We know how biotech and pharma work on both sides of a deal. We help your team build BD capability, find the right science, manage existing alliances and out-license assets outside your focus.

Anthony A. Hörning

Founder & CEO

Anthony A. Hörning

Anthony founded STA after more than 20 years at Novartis, most recently as Head of Alliance Management, General Medicines. He brings established pharma relationships and a deep understanding of how pharma partners assess an opportunity.

Previous Work Experience

  • Novartis10 years

    Head of Alliance Management, General Medicines, Pharmaceuticals

  • Novartis4 years

    Head of BD&L, Established Medicines

  • Novartis3 years

    CFO Brazil

  • Novartis5 years

    Head of Capital Markets & IR

  • J.P. Morgan10 years

    Senior Account Manager, European Desk, investment banking services

Adrien N. Hörning

Associate Partner

Adrien N. Hörning

Adrien joined the family business in 2023 after two years in investment banking and private equity, contributing deal analysis and valuation skills.

Education

Master’s in Accounting and Finance and Bachelor’s in Business Administration, University of St. Gallen (HSG).

  • Columbia University, (exchange semester)
  • Copenhagen Business School, (exchange semester)
  • WU Vienna, (exchange semester)

Previous Work Experience

  • J.P. Morgan, Zürich · Investment Banking Team
  • Verium AG, Zürich · Private Equity · Direct Investments Team
  • Capvis AG, Zug · Private Equity · Direct Investments Team
Publications & industry contributions
Good Partnering PracticesSwiss HLG · Framework & resourcesOrchestrating PartneringStrategic Alliance Magazine · InterviewWorkshop excerpt (video)

More publications & talks

Industry links
ASAPBasel Area Business & InnovationPLCDSwiss HLGVantage Partners

03 The Support

How we can support your existing Business Development and Alliance Management efforts

01

Alliance Management

Improve your partnerships

Most alliances fall short of what was promised at signing. We help you see why and get them back on track.

  • Alliance health checks and portfolio reviews
  • Individual coaching for key alliance management roles
  • Workshops for BD and AM teams

Led by Anthony Hörning, former Head of Alliance Management at Novartis.

Discuss your alliances ↗
Alliance health checkContinuous improvement
  1. 01
    Assess ongoing alliancesReview goals and performance.
  2. 02
    Draw conclusionsIdentify priorities for change.
  3. 03
    Implement findingsPut agreed actions into practice.
  4. 04
    Improve project successReduce risk and support progress.
Reassess and improve
Foundations for effective alliances

Select a foundation to explore key questions and STA support.

Key questions

  • Which platforms, indications and geographies do you want exposure to?
  • What are your must-have partner qualities and ideal financial profile for partnerships?
STA support

A sparring partner to discuss these questions and challenge your thinking.

02

In-Licensing

Find assets that fit your pipeline.

Tell us what you are looking for and we will search for matching assets. Or ask us about an asset we already represent.

  • Targeted in-licensing search mandates
  • Strategic fit and opportunity assessment
  • Introductions and partnering discussions
Partner interest profileInteractive example

Therapeutic areas

Modalities

Small moleculesAntibodiesCell & gene therapies

Phase interest

Choose the earliest and latest phases you are interested in.

PREFERRED ENTRY STAGEPhase 2a ongoing (exploratory POC)
DiscoveryCommercialization
CoM patent preference

A clear interest profile helps us focus the search on science that fits your strategy.

Discuss a search mandate ↗
Existing STA mandates

Interested in an asset we represent?

Tell us which opportunity caught your attention. We can discuss its fit and arrange the appropriate next steps.

Discuss an existing mandate ↗
03

Out-Licensing

Find the right partner for your science.

Give proprietary assets, deprioritized programmes and opportunities outside your strategic focus a path forward.

  • Prepare the asset and partnering strategy
  • Identify and engage suitable partners
  • Negotiate and establish the collaboration
Explore out-licensing support ↗

For Science

Prepare your asset and advance your partnering process.

Explore biotech advisory